FDA “Misrepresented” Ephedra Dosing With Use Of Old Label In Court – Emord
This article was originally published in The Tan Sheet
Executive Summary
FDA lawyers misrepresented product labeling for Nutraceutical Corporation's ephedra dietary supplements to a Utah appeals court by referencing a discontinued label that instructed consumers to take high doses of the product, according to law firm Emord & Associates
You may also be interested in...
Ephedra Imports Legal While Nutraceutical Appeal Underway – Emord
FDA's refusal to allow Hong Kong-based broker EMAX to import ephedra-containing dietary supplements into the U.S. violates an April 2005 court ruling which invalidated the agency's ban on the botanical, according to a lawsuit filed April 21 by the firm Emord & Associates
Utah Court Overturns Ephedra Ban For Low-Dose Products
A Utah federal court has barred FDA from enforcing its ban on ephedra products containing 10 mg or less of ephedrine alkaloids per daily dose
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement